Increased sPD-L1 levels were associated with better outcomes in esophageal and renal cell cancer patients, while in contrast in NSCLC and melanoma, high sPD-L1 levels were associated with poor survival [30,31,34,35]. The gene discussed is SPDL1; the disease is renal cell adenocarcinoma.